サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1272635

塞栓粒子の世界市場（～2027年）

Global Embolization Particle Market to 2027
出版日: | 発行: Market Research Future | ページ情報: 英文 113 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
塞栓粒子の世界市場（～2027年）
出版日: 2023年05月10日
発行: Market Research Future
ページ情報: 英文 113 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の塞栓粒子市場について調査分析し、市場力学、地域とセグメントの分析、企業プロファイルなどを提供しています。

目次

第1章 レポートのプロローグ

第2章 市場のイントロダクション

第3章 調査手法

第4章 市場力学

  • イントロダクション
  • 促進要因
    • インターベンショナルラジオロジーとインターベンショナル心血管手術に向けた塞栓粒子の需要の増大（影響の重み - 35%）
    • 塞栓術は、インターベンショナル手術に対して利用可能な最良の低侵襲の代替手段である（影響の重み - 30%）
    • さまざまな種類のがんの流行は、市場の成長を担う要因の1つである（影響の重み - 25%）
    • 有利な償還シナリオ（影響の重み - 10%）
  • 抑制要因
    • インターベンショナル神経放射線科医とインターベンショナル神経放射線科（INR）検査室の少なさ（影響の重み - 40%）
    • 厳格な規制規則（影響の重み - 60%）
  • 機会
    • マイクロスフェア技術における最近の進歩
  • メガトレンド
  • マクロ経済指標

第5章 市場要因の分析

  • ポーターのファイブフォース分析
  • バリューチェーン分析
    • 研究開発
    • 臨床試験・法的問題
    • 製造
    • マーケティング・販売
  • 購買活動、戦略、影響
  • 投資機会の分析
  • 塞栓粒子（リピオドール）の価格に対する影響：効果と影響
  • 塞栓術における償還の問題

第6章 世界の塞栓粒子市場：製品タイプ別

  • イントロダクション
  • 放射線塞栓スフェア
  • 薬剤溶出性ビーズ

第7章 世界の塞栓粒子市場：用途別

  • イントロダクション
  • 腫瘍
  • 泌尿器
  • 末梢血管疾患
  • 神経

第8章 世界の塞栓粒子市場：閉塞レベル別

  • イントロダクション
    • 近位
    • 遠位

第9章 世界の塞栓粒子市場：エンドユーザー別

  • イントロダクション
  • 病院・診療所
  • 外来センター

第10章 世界の塞栓粒子市場：地域別

  • イントロダクション
  • 南北アメリカ
    • 米国
    • カナダ
    • 南米
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • その他のアジア太平洋
    • 中東・アフリカ

第11章 競合情勢

  • イントロダクション
  • 企業シェア分析

第12章 企業プロファイル

  • BOSTON SCIENTIFIC CORPORATION
  • GUERBET
  • BTG INTERNATIONAL LTD
  • MEDTRONICS
  • SIRTEX
  • TERUMO
  • MERIT MEDICAL

第13章 MRFRの結論

  • 主な調査結果
    • CEOの視点から
    • アンメットニーズ
  • 注目すべき主要企業

第14章 付録

図表

LIST OF TABLES

  • TABLE 1 PRIMARY INTERVIEWS 18
  • TABLE 2 SAMPLE SIZE DETERMINATION OF END-USERS (HOSPITALS, CLINICS) 19
  • TABLE 3 AVERAGE PRICING OF LIPIODOL IN VARIOUS COUNTRIES (USD) 38
  • TABLE 4 GLOBAL EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 40
  • TABLE 5 GLOBAL EMBOLIZATION PARTICLE MARKET FOR RADIOEMBOLIZATION SPHERES, BY REGION, 2020-2027 (USD MILLION) 41
  • TABLE 6 GLOBAL EMBOLIZATION PARTICLE MARKET FOR DRUG ELUTING BEADS, BY REGION, 2020-2027 (USD MILLION) 42
  • TABLE 7 GLOBAL EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 43
  • TABLE 8 GLOBAL EMBOLIZATION PARTICLE MARKET FOR ONCOLOGY, BY REGION, 2020-2027 (USD MILLION) 45
  • TABLE 9 GLOBAL EMBOLIZATION PARTICLE MARKET FOR UROLOGY, BY REGION, 2020-2027 (USD MILLION) 46
  • TABLE 10 GLOBAL EMBOLIZATION PARTICLE MARKET FOR PERIPHERAL VASCULAR DISEASE, BY REGION, 2020-2027 (USD MILLION) 47
  • TABLE 11 GLOBAL EMBOLIZATION PARTICLE MARKET FOR NEUROLOGY, BY REGION, 2020-2027 (USD MILLION) 48
  • TABLE 12 GLOBAL EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 49
  • TABLE 13 GLOBAL EMBOLIZATION PARTICLE MARKET FOR PROXIMAL, BY REGION, 2020-2027 (USD MILLION) 50
  • TABLE 14 GLOBAL EMBOLIZATION PARTICLE MARKET FOR DISTAL, BY REGION, 2020-2027 (USD MILLION) 50
  • TABLE 15 GLOBAL EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 51
  • TABLE 16 GLOBAL EMBOLIZATION PARTICLE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2027 (USD MILLION) 52
  • TABLE 17 GLOBAL EMBOLIZATION PARTICLE MARKET FOR AMBULATORY CENTERS, BY REGION, 2020-2027 (USD MILLION) 53
  • TABLE 18 GLOBAL EMBOLIZATION PARTICLE MARKET, BY REGION, 2020-2027 (USD MILLION) 54
  • TABLE 19 AMERICAS EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020 & 2027 (USD MILLION) 56
  • TABLE 20 AMERICA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 57
  • TABLE 21 AMERICA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 58
  • TABLE 22 AMERICA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 58
  • TABLE 23 AMERICA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 59
  • TABLE 24 U.S. EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 59
  • TABLE 25 U.S. EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 60
  • TABLE 26 U.S. EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 60
  • TABLE 27 U.S. EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 61
  • TABLE 28 CANADA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 61
  • TABLE 29 CANADA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 62
  • TABLE 30 CANADA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 62
  • TABLE 31 CANADA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 63
  • TABLE 32 SOUTH AMERICA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 63
  • TABLE 33 SOUTH AMERICA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 64
  • TABLE 34 SOUTH AMERICA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 64
  • TABLE 35 SOUTH AMERICA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 65
  • TABLE 36 EUROPE EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 66
  • TABLE 37 EUROPE EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 67
  • TABLE 38 EUROPE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 68
  • TABLE 39 EUROPE EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 68
  • TABLE 40 EUROPE EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 69
  • TABLE 41 GERMANY EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 69
  • TABLE 42 GERMANY EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 70
  • TABLE 43 GERMANY EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 70
  • TABLE 44 GERMANY EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 71
  • TABLE 45 FRANCE EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 71
  • TABLE 46 FRANCE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 72
  • TABLE 47 FRANCE EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 72
  • TABLE 48 FRANCE EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 73
  • TABLE 49 UK EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 73
  • TABLE 50 UK EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 74
  • TABLE 51 UK EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 74
  • TABLE 52 UK EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 75
  • TABLE 53 ITALY EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 75
  • TABLE 54 ITALY EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 76
  • TABLE 55 ITALY EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 76
  • TABLE 56 ITALY EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 77
  • TABLE 57 SPAIN EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 77
  • TABLE 58 SPAIN EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 78
  • TABLE 59 SPAIN EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 78
  • TABLE 60 SPAIN EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 79
  • TABLE 61 REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 79
  • TABLE 62 REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 80
  • TABLE 63 REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 80
  • TABLE 64 REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 81
  • TABLE 65 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 82
  • TABLE 66 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 83
  • TABLE 67 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 84
  • TABLE 68 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 84
  • TABLE 69 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 85
  • TABLE 70 JAPAN EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 85
  • TABLE 71 JAPAN EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 86
  • TABLE 72 JAPAN EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 86
  • TABLE 73 JAPAN EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 87
  • TABLE 74 CHINA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 87
  • TABLE 75 CHINA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 88
  • TABLE 76 CHINA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 88
  • TABLE 77 CHINA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 89
  • TABLE 78 INDIA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 89
  • TABLE 79 INDIA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 90
  • TABLE 80 INDIA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 90
  • TABLE 81 INDIA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 91
  • TABLE 82 REPUBLIC OF KOREA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 91
  • TABLE 83 REPUBLIC OF KOREA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 92
  • TABLE 84 REPUBLIC OF KOREA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 92
  • TABLE 85 REPUBLIC OF KOREA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 93
  • TABLE 86 AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 93
  • TABLE 87 AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 94
  • TABLE 88 AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 94
  • TABLE 89 AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 95
  • TABLE 90 REST OF ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 95
  • TABLE 91 REST OF ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 96
  • TABLE 92 REST OF ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 96
  • TABLE 93 REST OF ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 97
  • TABLE 94 MIDDLE EAST & AFRICA EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION) 97
  • TABLE 95 MIDDLE EAST & AFRICA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 98
  • TABLE 96 MIDDLE EAST & AFRICA EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020-2027 (USD MILLION) 98
  • TABLE 97 MIDDLE EAST & AFRICA EMBOLIZATION PARTICLE MARKET, BY END USER, 2020-2027 (USD MILLION) 99

LIST OF FIGURES

  • FIGURE 1 GLOBAL EMBOLIZATION PARTICLE MARKET SHARE, BY PRODUCT TYPE, 2020 (%) 12
  • FIGURE 2 GLOBAL EMBOLIZATION PARTICLE MARKET SHARE, BY APPLICATIONS, 2020 (%) 13
  • FIGURE 3 GLOBAL EMBOLIZATION PARTICLE MARKET, BY REGION, 2020 (%) 14
  • FIGURE 4 MARKET STRUCTURE 16
  • FIGURE 5 RESEARCH METHODOLOGY 17
  • FIGURE 6 FORECAST MODEL 21
  • FIGURE 7 PORTERS FIVE FORCES MODEL 32
  • FIGURE 8 VALUE CHAIN: TISSUE MICROARRAY 34
  • FIGURE 9 GLOBAL EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE, 2020 & 2027 (USD MILLION) 41
  • FIGURE 10 GLOBAL EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 44
  • FIGURE 11 GLOBAL EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION, 2020 & 2027 (USD MILLION) 49
  • FIGURE 12 GLOBAL EMBOLIZATION PARTICLE MARKET, BY END USER, 2020 & 2027 (USD MILLION) 51
  • FIGURE 13 GLOBAL EMBOLIZATION PARTICLE MARKET, BY REGION, 2020 & 2027 (USD MILLION) 55
  • FIGURE 14 AMERICA EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020 (%) 57
  • FIGURE 15 EUROPE EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020 (%) 67
  • FIGURE 16 ASIA PACIFIC EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2020 (%) 83
  • FIGURE 17 GLOBAL EMBOLIZATION PARTICLE MARKET: COMPETITIVE LANDSCAPE 100
  • FIGURE 18 GLOBAL EMBOLIZATION PARTICLE MARKET: COMPANY SHARE ANALYSIS, 2020 (%) 101
目次
Product Code: MRFR/Pharma/3388-CR

Market Overview

A non-invasive therapy known as embolisation, the Endovascular Particle is a cutting-edge concept that intends to halt not only hemorrhage but also ways to stop blood circulation to a tumour in a logical order to diminish it or in readiness for total abolition. Few embolised particles or tiny materials are forcefully injected into the clinic's patients' critical veins during the advanced process known as embolisation particle in order to entirely block or stop the blood flow to conventional cancerous cells. A very small percentage of individuals who have pre-existing tumours that current surgery cannot entirely remove have the option of embolisation. Tumors that are too large to be cured with current ablation techniques can be treated with embolisation particles. Ablation can also use embolisation particles. Embolization does, without a doubt, limit some of the blood flow to the healthy liver tissue that is present inside the body, thus it might not be a good alternative for some people whose livers have been damaged by diseases like serious hepatitis- or cirrhosis-related disorders. A significant part of contemporary interventional radiology uses embolisation particles in a variety of treatments.

Segment Overview

Insights into various market segments, including Structure, Application, and Region, can be found in the global embolisation particle market. The degree of occlusion, contemporary application, end-user, and numerous product kinds are used to segment the global market.

Research organisations, traders, importers, exporters, suppliers, and industry end users are the main market participants. The idea is picking up steam. The businesses are concentrating more on enhancing their methods for product innovation.

Many embolisation particle markets are being broken down and researched regionally, including those in Europe, Asia Pacific, North America, and the rest of the world.

Regional Analysis

Without a question, North America is the market leader because to the significant presence of international competitors in this area and the rapid improvement of technology. Geography predicts that North America will account for the largest share of profits owing to the increased use of various cloud-based services by means of manufacturing systems and various distribution channels. In addition, the market for the Asia Pacific region is expected to expand quickly due to increased investment.

Major Players

Market industry participants include: Medtronics, GuerbetTerumoBTG International Ltd. Sirtex, Boston Scientific Corporation, and Merit Medical.

COVID 19 Impacts

The market analysis for embolisation particles and 215 other nations have both been impacted by COVID 19. Countries have implemented lockdowns to address the harmful consequences, which has hurt the market for embolisation particles. The epidemic presents the industry with a number of difficulties because it has an international impact. Many elements, including supply chain risk, distribution issues, a lack of workforce workers, and drastically reduced development activities, have had a major impact on current demand and supply. Consumers are not as engaged as they once were. There are significant strategic developments going on. Due to the rising demand from customers all over the world, MNCs are spending more in the market for embolisation particles.

TABLE OF CONTENTS

1 REPORT PROLOGUE

2 MARKET INTRODUCTION

  • 2.1 DEFINITION 15
  • 2.2 SCOPE OF THE STUDY 15
    • 2.2.1 RESEARCH OBJECTIVE 15
    • 2.2.2 ASSUMPTIONS 15
    • 2.2.3 LIMITATIONS 16

3 RESEARCH METHODOLOGY

  • 3.1 PRIMARY RESEARCH METHODOLOGY 18
  • 3.2 SECONDARY RESEARCH METHODOLOGY 19
  • 3.3 MARKET SIZE ESTIMATION 20
  • 3.4 MARKET SHARE ANALYSIS 22
  • 3.5 TRADE ANALYSIS 22
  • 3.6 MARKET PRICING APPROACH 22

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION 23
  • 4.2 DRIVER 24
    • 4.2.1 GROWING DEMAND OF EMBOLIZATION PARTICLES FOR INTERVENTIONAL RADIOLOGY AND INTERVENTIONAL CARDIOVASCULAR PROCEDURE (IMPACT WEIGHTAGE- 35%) 24
    • 4.2.2 EMBOLIZATION IS BEST MINIMALLY INVASIVE ALTERNATIVES AVAILABLE FOR THE

INTERVENTIONAL PROCEDURES (IMPACT WEIGHTAGE- 30%) 25

    • 4.2.3 INCREASING PREVALENCE OF VARIOUS TYPES OF CANCER IS ONE OF THE MAJOR FACTOR RESPONSIBLE FOR MARKET GROWTH (IMPACT WEIGHTAGE- 25%) 26
    • 4.2.4 FAVOURABLE REIMBURSEMENT SCENARIO (IMPACT WEIGHTAGE- 10%) 27
  • 4.3 RESTRAINTS 28
    • 4.3.1 LESS NUMBER OF INTERVENTIONAL NEURORADIOLOGISTS AND INTERVENTIONAL

NEURORADIOLOGY (INR) LABS (IMPACT WEIGHTAGE- 40%) 28

    • 4.3.2 STRICT REGULATORY RULES (IMPACT WEIGHTAGE-60% 29
  • 4.4 OPPORTUNITIES 30
    • 4.4.1 RECENT ADVANCES IN MICROSPHERE TECHNOLOGIES 30
  • 4.5 MEGA TRENDS 30
  • 4.6 MACROECONOMIC INDICATORS 31

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S 5 FORCES ANALYSIS 32
    • 5.1.1 BARGAINING POWER OF SUPPLIERS 33
    • 5.1.2 BARGAINING POWER OF BUYERS 33
    • 5.1.3 THREAT OF NEW ENTRANTS 33
    • 5.1.4 THREAT OF SUBSTITUTES 33
    • 5.1.5 INTENSITY OF RIVALRY 33
  • 5.2 VALUE CHAIN ANALYSIS 34
    • 5.2.1 R&D 34
    • 5.2.2 CLINICAL TEST & LEGAL ISSUES 35
    • 5.2.3 MANUFACTURING 35
    • 5.2.4 MARKETING & SALES 35
  • 5.3 PURCHASING ACTIVITIES, STRATEGIES AND IMPLICATIONS 36
  • 5.4 INVESTMENT OPPORTUNITY ANALYSIS 36
  • 5.5 PRICING IMPACT OF EMBOLIZATION PARTICLE (LIPIODOL): EFFECTS & IMPLICATIONS 37
  • 5.6 REIMBURSEMENT ISSUES IN EMBOLIZATION PROCEDURES 38

6 GLOBAL EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE

  • 6.1 INTRODUCTION 40
  • 6.2 RADIOEMBOLIZATION SPHERES 41
  • 6.3 DRUG ELUTING BEADS 42

7 GLOBAL EMBOLIZATION PARTICLE MARKET, BY APPLICATION

  • 7.1 INTRODUCTION 43
  • 7.2 ONCOLOGY 45
  • 7.3 UROLOGY 46
  • 7.4 PERIPHERAL VASCULAR DISEASE 47
  • 7.5 NEUROLOGY 48

8 GLOBAL EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION

  • 8.1 INTRODUCTION 49
    • 8.1.1 PROXIMAL 50
    • 8.1.2 DISTAL 50

9 GLOBAL EMBOLIZATION PARTICLE MARKET, BY END USER

  • 9.1 INTRODUCTION 51
  • 9.2 HOSPITALS & CLINICS 52
  • 9.3 AMBULATORY CENTERS 53

10 GLOBAL EMBOLIZATION PARTICLE MARKET, BY REGION

  • 10.1 INTRODUCTION 54
  • 10.2 AMERICAS 56
    • 10.2.1 U.S. 59
    • 10.2.2 CANADA 61
    • 10.2.3 SOUTH AMERICA 63
  • 10.3 EUROPE 66
    • 10.3.1 GERMANY 69
    • 10.3.2 FRANCE 71
    • 10.3.3 UK 73
    • 10.3.4 ITALY 75
    • 10.3.5 SPAIN 77
    • 10.3.6 REST OF EUROPE 79
  • 10.4 ASIA PACIFIC 82
    • 10.4.1 JAPAN 85
    • 10.4.2 CHINA 87
    • 10.4.3 INDIA 89
    • 10.4.4 REPUBLIC OF KOREA 91
    • 10.4.5 AUSTRALIA 93
    • 10.4.6 REST OF ASIA PACIFIC 95
    • 10.4.7 MIDDLE EAST & AFRICA 97

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION 100
  • 11.2 COMPANY SHARE ANALYSIS 101

12 COMPANY PROFILES

  • 12.1 BOSTON SCIENTIFIC CORPORATION 102
    • 12.1.1 COMPANY OVERVIEW 102
    • 12.1.2 FINANCIALS 102
    • 12.1.3 PRODUCTS 102
    • 12.1.4 STRATEGY 102
    • 12.1.5 KEY DEVELOPMENTS 102
  • 12.2 GUERBET 103
    • 12.2.1 COMPANY OVERVIEW 103
    • 12.2.2 FINANCIALS 103
    • 12.2.3 PRODUCTS 103
    • 12.2.4 STRATEGY 103
    • 12.2.5 KEY DEVELOPMENTS 103
  • 12.3 BTG INTERNATIONAL LTD 104
    • 12.3.1 COMPANY OVERVIEW 104
    • 12.3.2 FINANCIALS 104
    • 12.3.3 PRODUCTS 104
    • 12.3.4 STRATEGY 104
    • 12.3.5 KEY DEVELOPMENTS 104
  • 12.4 MEDTRONICS 105
    • 12.4.1 COMPANY OVERVIEW 105
    • 12.4.2 FINANCIALS 105
    • 12.4.3 PRODUCTS 105
    • 12.4.4 STRATEGY 105
    • 12.4.5 KEY DEVELOPMENTS 105
  • 12.5 SIRTEX 106
    • 12.5.1 COMPANY OVERVIEW 106
    • 12.5.2 FINANCIALS 106
    • 12.5.3 PRODUCTS 106
    • 12.5.4 STRATEGY 106
    • 12.5.5 KEY DEVELOPMENTS 106
  • 12.6 TERUMO 107
    • 12.6.1 COMPANY OVERVIEW 107
    • 12.6.2 FINANCIALS 107
    • 12.6.3 PRODUCTS 107
    • 12.6.4 STRATEGY 107
    • 12.6.5 KEY DEVELOPMENTS 107
  • 12.7 MERIT MEDICAL 108
    • 12.7.1 COMPANY OVERVIEW 108
    • 12.7.2 FINANCIALS 108
    • 12.7.3 PRODUCTS 108
    • 12.7.4 STRATEGY 108
    • 12.7.5 KEY DEVELOPMENTS 108

13 MRFR CONCLUSION

  • 13.1 KEY FINDINGS 109
    • 13.1.1 FROM CEO'S VIEW POINT 109
    • 13.1.2 UNMET NEEDS 109
  • 13.2 KEY COMPANIES TO WATCH 109

14 APPENDIX

  • 14.1 DISCUSSION BLUE PRINT 110
  • 14.2 REFERENCES 112